These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11695558)

  • 1. Criteria for the evaluation of studies in transgenic models.
    Popp JA
    Toxicol Pathol; 2001; 29 Suppl():20-3. PubMed ID: 11695558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
    Robinson DE; MacDonald JS
    Toxicol Pathol; 2001; 29 Suppl():13-9. PubMed ID: 11695549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CB6F1-rasH2 mouse: overview of available data.
    Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
    Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panel discussion on the application of alternative models to cancer risk assessment.
    Pettit SD
    Toxicol Pathol; 2001; 29 Suppl():191-5. PubMed ID: 11695557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53+/- hemizygous knockout mouse: overview of available data.
    Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
    Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and theEnvironment. Statement on ILSI/HESI research programme on alternative cancer models.
    Blain PG
    Toxicol Pathol; 2003; 31(2):254-7. PubMed ID: 12696588
    [No Abstract]   [Full Text] [Related]  

  • 9. Neonatal mouse model: review of methods and results.
    McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
    Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xpa and Xpa/p53+/- knockout mice: overview of available data.
    van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
    Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of human cancer risk: challenges for alternative approaches.
    Omenn GS
    Toxicol Pathol; 2001; 29 Suppl():5-12. PubMed ID: 11695561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expectations for transgenic rodent cancer bioassay models.
    Ashby J
    Toxicol Pathol; 2001; 29 Suppl():177-82. PubMed ID: 11695555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk.
    Robinson D
    Toxicol Pathol; 1998; 26(4):474-5. PubMed ID: 9715505
    [No Abstract]   [Full Text] [Related]  

  • 15. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI.
    MacDonald J; French JE; Gerson RJ; Goodman J; Inoue T; Jacobs A; Kasper P; Keller D; Lavin A; Long G; McCullough B; Sistare FD; Storer R; van der Laan JW
    Toxicol Sci; 2004 Feb; 77(2):188-94. PubMed ID: 14657512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highlights of International meeting on Alternative Methods of Carcinogenicity Testing, Leesburg, VA, November 1-3, 2000, Sponsored by the Health and Environmental Sciences Institute.
    Jollow DJ
    J Agromedicine; 2004; 9(2):427-9. PubMed ID: 19785235
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetically altered mouse models for identifying carcinogens.
    Tennant RW; Stasiewicz S; Mennear J; French JE; Spalding JW
    IARC Sci Publ; 1999; (146):123-50. PubMed ID: 10353386
    [No Abstract]   [Full Text] [Related]  

  • 18. Tg.AC genetically altered mouse: assay working group overview of available data.
    Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
    Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
    Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
    Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
    Mauthe RJ; Gibson DP; Bunch RT; Custer L
    Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.